HIV Preexposure Prophylaxis Clinical Trial
Official title:
A Multicenter, Observational Cohort to Study the Characteristics of Individuals Asking for Pre-exposure Prophylaxis (PrEP) and the Incidence of HIV and Other Sexually Transmitted Infections: 'The SwissPrEPared Study'
Nested within the SwissPrEPared Program, the "SwissPrEPared Study" - a large, multicentric, nation-wide cohort study - aims to longitudinally follow individuals asking for PrEP prescription over a period of 3 years.
Status | Recruiting |
Enrollment | 3000 |
Est. completion date | March 2030 |
Est. primary completion date | March 2030 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 16 Years to 120 Years |
Eligibility | Inclusion Criteria: - Participation in the SwissPrEPared program - Aged =16 years - HIV negative Exclusion Criteria: - Individuals unable to follow program procedures (e.g. language barriers, mental or psychiatric disorders) |
Country | Name | City | State |
---|---|---|---|
Switzerland | Kantonsspital Aarau | Aarau | Aargau |
Switzerland | Kantonsspital Baden | Baden | Aargau |
Switzerland | MedCenter Volta | Basel | Basel-Stadt |
Switzerland | Praxis dr. med. Clara Thierfelder | Basel | Basel Stadt |
Switzerland | Praxis Hammer | Basel | Basel-Stadt |
Switzerland | University Hospital Basel | Basel | Basel-Stadt |
Switzerland | Checkpoint Bern | Bern | |
Switzerland | University Hospital Bern | Bern | |
Switzerland | Spitalzentrum Biel - Centre hospitalier Bienne | Biel | Bern |
Switzerland | Kantonsspital Graubünden | Chur | Graubünden |
Switzerland | Médecine Interne/Infectiologie FMH | Cottens | Fribourg |
Switzerland | Hôpital du Jura | Delémont | Jura |
Switzerland | Cabinet Dr. Marta Buzzi | Geneva | |
Switzerland | Cabinet Malagnou 2 | Geneva | |
Switzerland | Checkpoint Geneva | Geneva | |
Switzerland | Praxis Emmanuelle Boffi | Geneva | |
Switzerland | University Hospital Geneva | Geneva | |
Switzerland | Medical and Therapeutic Centre La Lignière | Gland | Vaud |
Switzerland | Cabinet Dr. Erika Castro Batänjer | Lausanne | Vaud |
Switzerland | Cabinet Gare 10 | Lausanne | Vaud |
Switzerland | Cabinet Rumine 35 | Lausanne | Vaud |
Switzerland | Cabinet Rumine 9 | Lausanne | Vaud |
Switzerland | Checkpoint Lausanne | Lausanne | Waadt |
Switzerland | University Hospital Laussane | Lausanne | Waadt |
Switzerland | Kantonsspital Ticcino | Lugano | Ticcino |
Switzerland | Maihofpraxis | Luzern | |
Switzerland | Kantonsspital Münsterlingen | Münsterlingen | Thurgau |
Switzerland | Réseau Hospitalier Neuchâtelois | Neuchâtel | |
Switzerland | Kantonsspital Olten | Olten | Solothurn |
Switzerland | Fondation PROFA | Renens VD | Vaud |
Switzerland | Kantonspital St. Gallen | Saint Gallen | |
Switzerland | Spital Thun | Thun | Bern |
Switzerland | Kantonsspital Winterthur | Winterthur | Zürich |
Switzerland | Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich | Zurich | |
Switzerland | ARUD | Zürich | |
Switzerland | Checkpoint Zürich | Zürich | |
Switzerland | Dermatologisches Zentrum Zürich AG | Zürich | |
Switzerland | Praxis Kalkbreite | Zürich | |
Switzerland | Praxisgemeinschaft D29 | Zürich | |
Switzerland | Stadtspital Triemli | Zürich | |
Switzerland | Travel Clinic UZH | Zürich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich | Cantonal Hospital St. Gallen, Cantonal Hosptal, Baselland, Federal Office of Public Health, Switzerland, Positive Council Switzerland, Swiss HIV Cohort Study, University Hospital, Basel, Switzerland, University Hospital, Geneva, University Hospital, University of Bern, University of Lausanne Hospitals |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of individuals asking for PrEP | Number of individuals asking for PrEP | 10 years | |
Primary | Proportion of individuals qualifying for PrEP according to current guidelines | Proportion of individuals qualifying for PrEP according to current guidelines | 10 years | |
Primary | PrEP regime used (daily, intermittent, on-demand) | PrEP regime used (daily, intermittent, on-demand) | 10 years | |
Primary | Mode of drug supply (pharmacy versus online) | Mode of drug supply (pharmacy versus online) | 10 years | |
Primary | Adherence rates to programme | Adherence rates to programme assessed via lost to follow-up and dropouts | 10 years | |
Primary | Adherence rates to PrEP | Adherence rates to PrEP measured via self-report questionnaire | 10 years | |
Primary | Occurrence of side effects | Occurrence of side effects | 10 years | |
Primary | Prevalence of HIV | Prevalence of HIV | 10 years | |
Primary | Incidence of HIV | Incidence of HIV | 10 years | |
Primary | Prevalence of other STIs (syphilis, hepatitis B, hepatitis C, gonorrhoea, chlamydia, mycoplasma genitalium) | Prevalence of other STIs (syphilis, hepatitis B, hepatitis C, gonorrhoea, chlamydia, mycoplasma genitalium) | 10 years | |
Primary | Incidence of other STIs (syphilis, hepatitis B, hepatitis C, gonorrhoea, chlamydia, mycoplasma genitalium) | Incidence of other STIs (syphilis, hepatitis B, hepatitis C, gonorrhoea, chlamydia, mycoplasma genitalium) | 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04754139 -
A Promotion and Implementation Project of HIV Pre-Exposure Prophylaxis Among High Risk Population
|
N/A | |
Completed |
NCT02074891 -
Sustainable Healthcenter Implementation PrEP Pilot Study
|
||
Completed |
NCT04424524 -
Streamlining the Efficiency of PrEP Implementation
|
||
Completed |
NCT04652700 -
Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
|
Phase 3 |